Pulmonary hypertension (PH) is a progressive disorder that causes significant morbidity and mortality despite existing therapies. PH pathogenesis is characterized by metabolic derangements that increase pulmonary artery smooth muscle cell (PASMC) proliferation and vascular remodeling. PH-associated decreases in peroxisome proliferator-activated receptor g (PPARg) stimulate PASMC proliferation, and PPARg in coordination with PPARg coactivator 1a (PGC1a) regulates mitochondrial gene expression and biogenesis. To further examine the impact of decreases in PPARg expression on human PASMC (HPASMC) mitochondrial function, we hypothesized that depletion of either PPARg or PGC1a perturbs mitochondrial structure and function to stimulate PASMC proliferation. To test this hypothesis, HPASMCs were exposed to hypoxia and treated pharmacologically with the PPARg antagonist GW9662 or with siRNA against PPARg or PGC1a for 72 hours.
pressure (2, 3) . Despite recent pharmacological advances in PH therapy that ameliorate imbalances in the production of vasodilating and vasoconstricting mediators, current therapeutic approaches largely fail to reverse the underlying derangements in metabolism and proliferation in cells of the pulmonary vasculature. These observations suggest that interventions that target and reverse metabolic and proliferative abnormalities in pulmonary vascular wall cells might be more effective for PH treatment.
Peroxisome proliferator-activated receptor g (PPARg), a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors, plays an important role in regulating a variety of fundamental cellular processes, including metabolism, proliferation, and inflammation (4) . For example, PPARg is expressed in pulmonary vascular endothelial cells and smooth muscle cells (SMCs), where it participates in the regulation of normal pulmonary vascular function (5) . PPARg expression is decreased in the vascular lesions of patients with idiopathic pulmonary arterial hypertension (PAH) (6) , and in cellular studies, depletion of PPARg was sufficient to promote development of the PH phenotype by upregulating cell cycle-related genes and angiogenesisrelated genes in pulmonary artery endothelial cells (7) , and to promote the proliferation of human pulmonary artery SMCs (HPASMCs) (8) . In contrast, pharmacological PPARg activation decreased PH in experimental models (9, 10) and favorably altered transcriptional and post-transcriptional pathways and the levels of vasoactive mediators involved in PH pathogenesis (9) (10) (11) . PPARg activation using the thiazolidinedione ligand rosiglitazone decreased pulmonary artery remodeling, muscularization of distal pulmonary arterioles, and SMC proliferation in rats subjected to chronic hypoxia (HYP) (12) , and reversed right ventricular hypertrophy and PH in insulin-resistant, apolipoprotein E-deficient mice fed a high-fat diet (13) . Combined with evidence that mice with vascular-targeted PPARg deletion develop PH (8) , these studies indicate that decreases in PPARg contribute to PH pathogenesis. The current study seeks to further explore the role of PPARg in the underlying metabolic derangements that contribute to SMC proliferation.
PPARg activates the promoter of PPARg coactivator 1a (PGC1a), a 795-amino-acid protein that coordinates nuclear and mitochondrial gene expression and also is a transcriptional coactivator of PPAR (14) . In PH, metabolic derangements related to reductions in the number of mitochondria and fragmentation of existing mitochondria (15) (16) (17) underlie phenotypic changes in pulmonary vascular wall cells (18) , such as SMC proliferation. In human and experimental PH, decreased expression of PGC1a contributes to mitochondrial fragmentation and proliferation, which are in part related to changes in mitochondrial number, structure, and function (19) . PGC1a also contributes to the adaptive response of PASMCs to HYP (20) . Collectively, these observations suggest that losses of PPARg and PGC1a may mutually contribute to PASMC proliferation. The current study identifies novel roles for PPARg in the regulation of SMC mitochondria that contribute to metabolic dysfunction and proliferation in pulmonary vascular wall cells.
This study also further defines the molecular mechanisms whereby decreases in PPARg stimulate metabolic derangements that are associated with increased pulmonary vascular cell proliferation. We previously reported that HYP decreased PPARg in vitro and in vivo (21) . Our current findings demonstrate that HYP exposure also decreases PGC1a expression, attenuates expression of mitochondrial proteins, and increases SMC proliferation. In addition, they demonstrate that short interfering RNA (siRNA)-mediated depletion of either PPARg or PGC1a is sufficient to stimulate mitochondria-derived H 2 O 2 and alter mitochondrial metabolism and function, which induce SMC proliferation. PGC1a activation using adenovirus overexpression reversed these HYP-induced HPASMC derangements. Taken together, these findings identify PPARg as a critical regulator of PASMC mitochondrial metabolism and proliferation, and illustrate mechanisms whereby decreases in this receptor could potentially contribute to PH pathogenesis.
Methods

In Vitro HPASMC Studies
HPASMCs were purchased from Lonza and Sci-Cell. HPASMC monolayers were grown at 37 8 C in a 5% CO 2 atmosphere and cultured in complete SmGM-2 medium (Lonza) containing 5% fetal calf serum, growth factors, and antibiotics as previously described (22) . Cells were cultured in a HYP chamber (1% O 2 ; Biospherix) or cell culture incubator (normoxia [NOR], 21% O 2 ) for 72 hours. HPASMC passages 2-9 were used for all experimental studies.
Knockdown or Overexpression of PPARg and PGC1a
To knock down PPARg in HPASMC, the PPARg antagonist GW9662 (5-10 mM; Sigma-Aldrich) or PPARg siRNA (100 nM; Dharmacon) was used as previously described (8) . To attenuate PGC1a, PGC1a siRNA (10 nM; Integrated DNA Technologies Inc.) was used. An adenovirus overexpressing PGC1a,
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ORIGINAL RESEARCH
AdPGC1a (a gift from Dr. Russ Price, Emory University), was used. Briefly, cells (40-50% confluent) were incubated for 3 hours with Opti-MEM (Life Technologies), transfected with siRNA using Lipofectamine RNAi reagent (Life Technologies) or treated with AdPGC1a for 4 hours, and grown in complete growth media for 72 hours. These HPASMCs were compared with cells transfected with scrambled siRNA (SCR) or treated with an adenovirus expressing green fluorescent protein (AdGFP) as an experimental control.
HPASMC Proliferation
HPASMCs were cultured in 12-well plates in complete medium, followed by 72 hours of HYP or GW9662 treatment or siRNA transfection. HPASMCs (75-85% confluent) were trypsinized in 500 ml trypsin, and a 1:1 cell suspension dilution with trypan blue was performed. Cells were counted in triplicate using a hemocytometer and expressed as mean cell counts 6 SEM relative to NOR, control DMSO vehicle, or SCR.
Analysis of mRNA, Protein, and Mitochondrial Alterations
Target mRNA levels were measured and quantified by qRT-PCR with specific human, mouse, and rat primer sequences as outlined in Table E1 
Statistical Analysis
Data were analyzed using Student's t test or two-way ANOVA followed by Tukey's post hoc test in GraphPad Prism version 6 (GraphPad) to determine the significance of the treatment effects. Statistical significance was set at an a-value of P < 0.05.
Results
HYP, PPARg Knockdown, or PGC1a Knockdown Increases HPASMC Proliferation
In previous studies, exposure to HYP regimens sufficient to induce PH in experimental animals in vivo (24) or to stimulate proliferation in HPASMC in vitro (9, 21, 22) was shown to significantly decrease lung-tissue or cellular levels of PPARg, respectively. Here, to further explore the relationships among PPARg, PGC1a, and PASMC proliferation, we treated cells with HYP, GW9662, siPPARg, or siPGC1a for 72 hours. HPASMC proliferation was measured by cell counting. We previously reported that HYP (21) or siPPARg (8) treatment regimens depleted PPARg levels by 50%. increase in proliferation caused by the combination of siRNAs was not significantly greater than that observed with each siRNA alone ( Figure 1C Figure 2C ); the expression of mitochondrial-specific proteins, including heat shock protein family A member 9 (GRP75; Figure 2D ) and voltage-dependent anion-selective channel (VDAC; Figure 2E ); and mRNA levels of mitofusin-2 (MFN2; Figure 2F ). These data, demonstrating decreases in mitochondrial mass, along with evidence of increased mitochondrial reactive oxygen species (ROS) generation (Figures 2A and 2B) , suggested an increase in mitochondrial fission (27) . Consistent with this, confocal microscopy of HPASMCs labeled with MitoTracker Orange (Thermo Fisher Scientific) demonstrated that siPPARg decreased the overall volume of mitochondria but increased the number of labeled mitochondria per cell ( Figure 2G ). To further examine the functional correlates of these siPPARg-induced alterations in mitochondrial structure, we determined the HPASMC mitochondrial bioenergetics. Treatment with siPPARg decreased HPASMC OCR ( Figure 3A ) and diminished basal respiration ( Figure 3B ), ATP production ( Figure 3C ), proton leak ( Figure 3D ), and maximal respiration ( Figure 3E ).
Loss of PPARg Decreases PGC1a Expression In Vitro and In Vivo
PPARg and PGC1a are mutually activating central metabolic regulators (14, 28) . Because the PGC1a promoter is regulated by PPARg, we sought to determine whether alterations in PPARg expression modulate PGC1a levels. HPASMCs were treated with the PPARg antagonist GW9662 or with siPPARg for 72 hours. Compared with vehicle, GW9662 decreased the levels of PGC1a mRNA ( Figure 4A ) and protein ( Figure 4B ). Similarly, compared with SCR, siPPARg decreased both PGC1a mRNA ( Figure 4C ) and protein ( Figure 4D) levels. These data demonstrate that loss of PPARg decreases PGC1a expression in HPASMCs.
Because HYP was previously shown to downregulate PPARg expression in HPASMCs in vitro (21) and in mouse lungs in vivo (9), stimulating PASMC proliferation and PH, respectively, we examined lung PGC1a in C57BL/6J mice exposed to HYP (10% O 2 ) or NOR (21% O 2 ) for 3 weeks. HYP decreased mouse lung PGC1a mRNA ( Figure 5A ) and protein levels ( Figure 5B) . Similarly, PGC1a mRNA ( Figure 5C ) and protein ( Figure 5D ) levels were depleted in HPASMC treated with HYP (1% O 2 ) for 72 hours. Collectively, these data indicate that HYP decreases expression of both PPARg and PGC1a in mouse lungs and HPASMCs.
Because depletion of PPARg perturbed mitochondrial structure and function, and because PGC1a is a critical PPARg cofactor in regulating mitochondrial mass and bioenergetics, we further examined the relationship between decreases in HPASMC PPARg and PGC1a. HPASMCs were transfected with SCR or siPGC1a for 72 hours, which knocked down PGC1a mRNA ( Figure E1A ) and protein ( Figure E1B ) levels. Treatment with siPGC1a did not affect PPARg mRNA levels ( Figure E1C ), suggesting that the effects of PPARg are upstream of PGC1a in HPASMCs. Similar to the effects of induced knockdown of PPARg, siPGC1a diminished TFAM mRNA levels ( Figure E2A) and perturbed the HPASMC mitochondrial bioenergetic profile ( Figures E2B-E2F ). Taken together, these data demonstrate that decreases in either PPARg or PGC1a are sufficient to alter HPASMC mitochondrial structure and function. Because decreases in PPARg or PGC1a are sufficient to stimulate HPASMC proliferation, these data indicate that targeting the PPARg-PGC1a axis is a promising therapeutic strategy for reversing metabolic and proliferative derangements in pulmonary vascular wall cells.
HYP Decreases Expression of Mitochondrial Proteins in HPASMCs
Because HYP downregulated PPARg expression in HPASMCs in vitro (21) and siPPARg induced HPASMC mitochondrial fragmentation (Figure 2) , we sought to determine the effect of HYP on the expression of HPASMC mitochondrial proteins. Treatment with HYP caused decreases in HPASMC TFAM ( Figure 6A ), GRP75 ( Figure 6B ), and VDAC ( Figure 6C ) protein expression, comparable to those caused by siRNA-mediated PPARg knockdown. To confirm these results in an in vivo experimental model of PH, we used a hypoxic SU5416 rat model of PH. Compared with the lungs isolated from normoxic SU5416 rats, the lungs from hypoxic SU5416 rats showed decreased mRNA levels of PGC1a ( Figure E3A ), TFAM ( Figure E3B ), GRP75 ( Figure E3C ), VDAC ( Figure E3D ), and MFN2 ( Figure  E3E ). These data further support the postulate that HYP-induced loss of PPARg mediates derangements in mitochondrial structure and function in HPASMC, and that these mitochondrial derangements are not specific to a single rodent model of PH.
Overexpression of PGC1a Reverses HYP-Induced HPASMC Proliferation
Because HYP decreased PGC1a expression in mouse lungs and HPASMCs ( Figure 5 ), and knockdown of PGC1a increased HPASMC proliferation ( Figure 1C) , we sought to determine whether an adenovirus overexpressing PGC1a could reverse HYP-induced HPASMC derangements. The PGC1a overexpression adenovirus increased PGC1a mRNA and protein levels ( Figures  E4A and E4B ) in a dose-dependent manner, but did not affect PPARg mRNA and protein levels ( Figures E4C and E4D ). PGC1a adenoviral overexpression reversed HYPinduced HPASMC proliferation ( Figure E5 ). Collectively, these data indicate the critical importance of PPARg and PGC1a for HYP-induced HPASMC derangements.
Discussion
The pathogenesis of PH is complex and characterized by alterations in metabolism and proliferation in cells of the pulmonary vascular wall (2) . Chronic HYP constitutes a common stimulus for experimental PH in rodent models (29) . HYP promotes a variety of molecular and cellular changes in the lung, including decreases in PPARg expression and activity (21) . PPARg expression is downregulated in the lungs of rodents with HYP-induced PH in vivo (24, 30) and in HPASMCs exposed to HYP in vitro (21) . PPARg downregulation in these models is comparable to that reported in the vascular lesions (6) of patients with PAH (31) . Further, SMC-targeted PPARg deletion is sufficient to cause PH in mice (8) . Taken together, these observations suggest that decreases in PPARg represent a common pathogenic factor in PH. The precise mechanisms by which reductions in PPARg promote PASMC proliferation and pulmonary vascular remodeling continue to be defined. The current study further clarifies molecular pathways linking decreases in PPARg to alterations in cell metabolism and proliferation by showing that HYP or decreases in PPARg in HPASMCs deplete PGC1a and cause derangements in mitochondrial structure and function that stimulate HPASMC proliferation (Figure 7 ). These novel results identify PPARg and PGC1a as potential targets in PH pathogenesis and therapy. Current evidence indicates that metabolic derangements (18) , including decreased mitochondrial numbers, mitochondrial fragmentation (15) (16) (17) , and a shift toward glycolysis-derived ATP production, contribute to pulmonary vascular wall cell phenotypic changes that cause pulmonary vascular remodeling. PPARg is a central metabolic regulator that activates PGC1a, which coordinates mitochondrial gene expression and in turn activates PPAR. Our data demonstrate that HYP decreases PPARg and PGC1a, and that decreases in PPARg are sufficient to diminish PGC1a expression (Figures 4 and 5) . Our findings further demonstrate that loss of PPARg or PGC1a is sufficient to stimulate HPASMC proliferation (Figure 1 ). PGC1a stimulates mitochondrial biogenesis (32) via activation of nuclear respiratory factor 1, which increases expression of TFAM (33) and nuclear respiratory factor 2 (32). TFAM is a mitochondrial-specific transcription factor that is required for maintenance of mitochondrial DNA copy number and the integrity of respiration (33) . Depletion of PPARg (Figure 2 ) or PGC1a ( Figure E2 ) by siRNA or HYP ( Figure 6 ) decreased expression of the mitochondrial-specific proteins TFAM, GRP75, and VDAC in HPASMCs, and these same targets were decreased in lung tissue from HYP-exposed, SU5416-treated rats ( Figure E3 ). Further, activation of PPARg (34) or PGC1a overexpression ( Figure E5 ) attenuated HYPinduced HPASMC proliferation, supporting the importance of PPARg and PGC1a in HYP-induced HPASMC derangements. VDAC is located on the outer membrane of the mitochondria and forms the permeability transition pore complex, which is responsible for the release of mitochondrial products that trigger apoptosis (35) . GRP75 interacts with VDAC and modulates its channel properties (36) . Therefore, PPARg or PGC1a depletion-mediated decreases in GRP75 and PGC1a mRNA (C) and protein (D) levels were measured. The mRNA (n = 5-6) and protein (n = 8) levels of the targets were normalized to housekeeping genes and proteins and expressed as mean 6 SEM fold change relative to NOR. *P , 0.05 versus NOR. Readers may view the uncut gels for Figure 5B in the data supplement.
VDAC expression may promote HPASMC proliferation ( Figure 1 ) by inhibiting apoptosis. Consistent with this postulate, siRNA-mediated PPARg knockdown decreased HPASMC apoptosis (caspase-3 activity) (34) . siPPARg-mediated decreases in MFN2 mRNA levels, coupled with decreases in mitochondrial volume and increased numbers of mitochondria per HPASMC (Figure 2 ), also suggest fragmentation of existing mitochondria, which may contribute to the impaired mitochondrial bioenergetics shown in Figure 3 . Loss of PPARg ( Figure 3A ) or PGC1a ( Figure E2B ) decreased the overall mitochondrial bioenergetic profile in HPASMCs and suppressed basal OCR, proton leak, ATP production, and maximal respiration, consistent with broad derangements in mitochondrial function. Our results indicate that these alterations in mitochondrial function, secondary to depletion of PPARg or PGC1a, are related in part to (1) decreased mitochondrial biogenesis, as evidenced by decreases in PGC1a ( Figures  4C and 4D) , TFAM, GRP75, and VDAC ( Figures 2C-2E) , and (2) increased mitochondrial fission, as evidenced by decreases in MFN2 and mitochondrion volume and increases in the number of mitochondria per cell (Figures 2F and 2G) . In a previous study, SMCs isolated from the pulmonary vessels of rats with monocrotaline-induced PH showed decreases in mitochondrial function due to loss of complex I assembly, decreased activities of complexes II and III, and increased levels of mitochondrial-derived ROS, membrane potential, and glycolysis (37) . Our findings extend those observations by demonstrating that decreases in PPARg are sufficient to increase mitochondrial-derived ROS generation ( Figure 2 ) and decrease mitochondrial function (Figure 3) . Ongoing studies will further characterize the mitochondrial derangements caused by loss of PPARg by defining the uncoupling protein activity, mitochondrial membrane potential, and integrity of the electron transport chain.
Several limitations in our study merit additional consideration. First, it is well recognized that the mouse model of HYPinduced PH used in our studies fails to recapitulate many characteristics of PH in humans (29) . Determining the relevance of these pathways to human PH will require additional studies employing cells or tissues isolated from PH patients. However, because PPARg is also decreased in the lungs and pulmonary vascular cells of patients with PAH (6), and because decreases in PPARg are sufficient to induce PH in experimental animals (38) , our findings suggest that decreases in PPARg may represent a common pathogenic stimulus in PH regardless of etiology or species. Second, although our in vivo HYP studies in mice suggest that pathways defined in hypoxic HPASMCs in vitro are also seen in vivo, our data do not define which specific pulmonary vascular cells sustain HYP-induced depletion of PPARg and PGC1a in vivo. Therefore, the effects of alterations in PPARg or PGC1a in other cell types in the vascular wall or in circulating immune cells on PH pathogenesis must also be considered (39) (40) (41) . For example, previous work demonstrated depleted PPARg levels in pulmonary artery endothelial cells (10) in PH. In addition, loss of bone morphogenetic protein receptor type 2 led to reductions in PGC1a, mitochondrial dysfunction, and a propensity to undergo apoptosis after HYP reoxygenation (42) , suggesting that these derangements are not confined to a single cell compartment. Third, although the present study does not specifically address the mechanisms by which HYP decreases PPARg in vitro or in vivo, our published studies have defined both transcriptional (21, 22) and post-translational (10) mechanisms that are activated by HYP to decrease PPARg levels. Finally, the length of time in which pulmonary vascular SMCs display proliferative responses to HYP in vivo is not well defined and may be limited (43) (44) (45) . Therefore, translating our in vitro findings to the pathobiology of PH in vivo will require more rigorous studies linking temporal and cell compartmentspecific alterations in PPARg and PGC1a to mitochondrial, metabolic, and proliferative derangements that cause pulmonary vascular remodeling. The current study extends previous reports to demonstrate a novel role for PPARg, through modulation of PGC1a, in regulating mitochondrial structure, function, and cellular metabolism in pulmonary vascular wall cells. Because PPARg or PGC1a knockdown stimulated HPASMC proliferation (Figure 1 ) and comparable derangements in mitochondrial protein expression and bioenergetics ( Figures  2, 3 , and E2), and because manipulation of PPARg regulated PGC1a, whereas manipulation of PGC1a had no effect on PPARg ( Figures E1 and E4 ), our findings collectively support a model in which PPARg regulates mitochondrial bioenergetic function through PGC1a. Although a metabolomic analysis of late-stage human PAH lung samples suggested that derangements in metabolism may differ according to the stage and severity of disease (46) , our studies along with previous reports provide evidence that depletion of PPARg causes metabolic derangements in pulmonary vascular wall cells and proliferative cellular phenotypes. Because loss of PPARg function has been implicated in diverse disorders (5), discovering common pathways that link PPARg downregulation to mitochondrial dysfunction may shed light on other disorders that share similar pathobiological mechanisms. Our findings identify additional mechanistic pathways whereby PPARg activation could potentially decrease metabolic derangements. Pharmacological activation of PPARg using rosiglitazone was previously shown to decrease chronic HYP-induced PH, right ventricular hypertrophy, and vessel thickness (24) . Taken together, these considerations suggest that therapeutic strategies that target PPARg have the potential to mitigate the fundamental metabolic derangements that cause vascular cell hyperproliferation and vascular remodeling during PH pathogenesis. n Author disclosures are available with the text of this article at www.atsjournals.org.
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Altered Mitochondrial Structure and Function Figure 7 . Summary schematic. HYP decreases PPARg expression, leading to diminished PGC1a expression. Loss of PPARg and the subsequent loss of PGC1a alter mitochondrial structure through decreased expression of TFAM, GRP75, VDAC, and MFN2, and impair mitochondrial function and bioenergetics. These mitochondrial derangements may contribute to the proliferation of HPASMCs observed under chronic hypoxic conditions.
